"We are now embarking on a new Long March, and we must start all over again!" Xi Jinping said.Marketsread more
U.S. aviation officials believe a bird strike may have led to the deadly crash of an Ethiopian Airlines Boeing 737 Max in March, according to a person familiar with the...Aerospace & Defenseread more
Sales of existing U.S. homes fell 0.4% in April compared with March to a seasonally adjusted annualized rate of 5.19 million units, according to the National Association of...Real Estateread more
The move, which was expected, has set up an early legal test of the president's strategy of fighting off congressional oversight by rejecting the legitimacy of subpoenas he...Politicsread more
"Let me be clear: this committee will hear Mr. McGahn's testimony, even if we have to go to court to secure it," Nadler said.Politicsread more
Morgan Stanley analysts said the reduction was driven by concerns around Chinese demand for Tesla products.Autosread more
The Fed should take its cues from falling bond yields and lower short-term interest rates, says conservative economist Art Laffer.Economyread more
Leuthold Group's Jim Paulsen sees a silver lining as the U.S.-China trade war rattles the market.Trading Nationread more
The FDA struck the wrong balance on its oversight of the e-cigarette industry, former commissioner Scott Gottlieb said Tuesday at CNBC's Healthy Returns conference.Healthy Returnsread more
Coca-Cola is partnering with Netflix to bring back New Coke to promote the third season of "Stranger Things."Food & Beverageread more
For every 5% drop in Greater China sales, Apple's earnings per share should fall about 15 cents, Credit Suisse tells clients.Investingread more
Johnson & Johnson said Wednesday it expects 10 new drugs to be launched by 2019—each with the potential to exceed $1 billion in revenue—and plans more than 40 line extensions of existing and new medicines.
"You're going to have some wins and some that don't turn out quite the way you expect," Chairman and CEO Alex Gorsky told CNBC's "Squawk Box " in an interview. "But overall we're very confident ... particularly based on what we've been able to do over the past several years." J&J said it has launched 14 new products since 2009—seven of which already exceed or are on track to achieve sales in excess of $1 billion during 2015.
The health-care giant expects these moves to provide momentum to sustain above-industry compound annual growth through 2019.
At its biennial pharmaceutical analyst meeting at its New Jersey headquarters Wednesday, J&J also announced plans to file a licensing application with the Food and Drug Administration for daratumumab in double refractory multiple myeloma. (Tweet This)
"It's just one indication of the payoff the patients are getting—that we're getting—from the investments that we've made in the oncology area," Gorsky said.
The submission will be based on Phase 2 data, which will be presented at the upcoming annual meeting of the American Society of Clinical Oncology. The ASCO gathering begins at the end of the month.